Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Oral complement factor D inhibitors

An alkyl, cycloalkyl technology, applied in the field of oral complement factor D inhibitors, which can solve problems such as destruction, generation of holes or holes, etc.

Pending Publication Date: 2022-05-13
BIOCRYST PHARM INC
View PDF18 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Subsequently, complement proteins create holes, or pores, in the invading organism, leading to its destruction

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oral complement factor D inhibitors
  • Oral complement factor D inhibitors
  • Oral complement factor D inhibitors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0348] Now that the invention has been described in detail, it will be more clearly understood by reference to the following examples, which are included herein for purposes of illustration only and are not intended to limit the invention.

[0349] plan 1

[0350]

[0351] Preparation of 2-((5-(3-(aminomethyl)phenyl)benzofuran-3-yl)methoxy)benzoic acid (1f)

[0352] Step-1: Preparation of methyl 2-((5-bromobenzofuran-3-yl)methoxy)benzoate (1c)

[0353] To a solution of 5-bromo-3-(bromomethyl)benzofuran (1a) (250mg, 0.862mmol; CAS#137242-43-4), potassium carbonate (477mg, 3.45mmol) in acetone (3mL) Methyl 2-hydroxybenzoate (1b) (157 mg, 1.035 mmol; CAS# 119-36-8) was added. The resulting mixture was stirred overnight at room temperature. The suspension was filtered through a pad of celite, and the filtrate was concentrated to dryness in vacuo. The obtained residue was purified by flash column chromatography [silica gel (12 g), eluting with 0-50% EtOAc / hexanes] to afford ...

Embodiment 334

[3749] ICs for compounds were calculated according to the procedure reported in U.S. Patent 6,653,340 B1, e.g., column 74 (incorporated by reference) 50 value (ie, the concentration of compound that inhibits 50% of the enzyme activity).

[3750] Specifically, compounds were dissolved in stock solutions in DMSO at 10.0 or 100 mM. Add a portion of this stock solution to the assay buffer to a final volume of 50 μL. Controls included buffer alone and enzyme solutions to which DMSO was added. Substrate is added to the wells either immediately or after incubation at room temperature. The reaction rate was measured spectrophotometrically by generating product at 405 nm for 600 seconds. The background absorbance at 690 nm was measured for each well and subtracted from the absorbance at 405 nm.

[3751] The reaction rate of the enzyme alone is compared to the rate of the enzyme in the presence of the inhibitor, and the percent inhibition is calculated as follows:

[3752] Percent in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
optical rotationaaaaaaaaaa
optical rotationaaaaaaaaaa
Login to View More

Abstract

Compounds of Formula (I) and pharmaceutically acceptable salts thereof are disclosed, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such compounds, and methods of using the compounds and compositions to treat or prevent diseases or conditions characterized by aberrant complement system activity.

Description

[0001] related application [0002] This application claims priority to U.S. Provisional Patent Application No. 62 / 912,929, filed October 9, 2019. Background technique [0003] The complement system is the branch of an organism's immune system that enhances the ability of antibodies and phagocytes to destroy foreign particles, such as pathogens, and remove them from the organism. The complement system comprises a group of plasma proteins that work together to attack the extracellular forms of pathogens and induce a cascade of inflammatory responses to help fight infection. Complement activation can proceed via several pathways. For example, complement activation can occur spontaneously in response to certain pathogens or by antibodies that bind to the pathogen. When complement proteins are activated, a cascade is triggered whereby one complement protein induces the activation of the next protein in the sequence. Activation of a small number of complement proteins at the beg...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/506A61K31/519A61K31/5377
CPCC07D307/80C07D333/56C07D471/04C07D209/12C07D231/56C07D405/04C07D407/12C07D405/06C07D273/04C07D491/048C07D405/12C07D417/12C07D495/04C07C217/48A61K31/343A61K31/381A61K31/437A61K31/404A61K31/416A61K31/5377A61K31/506A61P25/00A61P25/28A61P13/12A61P9/00A61P7/00A61P27/02C07D407/14C07D275/04C07D405/10C07D493/04C07D401/04
Inventor P·L·科蒂安Y·S·巴布张维河吕鹏程A·E·斯保尔丁吕魏党昭K·拉曼
Owner BIOCRYST PHARM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com